Global Furmonertinib Mesylate Supply, Demand and Key Producers, 2026-2032
The global Furmonertinib Mesylate market size is expected to reach $ 1934 million by 2032, rising at a market growth of 11.6% CAGR during the forecast period (2026-2032).
In 2025, global Furmonertinib Mesylate Tablets production reached approximately 380,000 units.Furmonertinib Mesylate is an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily used for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations or the T790M resistance mutation. It works by selectively and irreversibly inhibiting the kinase activity of mutant EGFR, thereby blocking tumor cell proliferation and survival signaling pathways and suppressing tumor growth. Furmonertinib mesylate is characterized by high selectivity for mutant EGFR, good central nervous system penetration, and a relatively manageable safety profile, making it clinically valuable in the treatment of advanced non-small cell lung cancer.
Furmonertinib Mesylate, as a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), operates in a rapidly developing and highly competitive segment of the non-small cell lung cancer (NSCLC) targeted therapy market, particularly demonstrating strong competitiveness in patients with EGFR mutations and T790M resistance mutations. With the large population of lung cancer patients and the continuous improvement in the penetration of genetic testing, the demand for precision medicine is steadily increasing, providing a solid market foundation for this class of drugs.
From a competitive landscape perspective, imported originator drugs represented by Osimertinib have long dominated the market. However, furmonertinib mesylate, leveraging its domestic R&D advantages, price competitiveness, and potential efficacy in patients with central nervous system metastases, is gradually gaining market share in China.
On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although healthcare cost-control measures and volume-based procurement policies continue to exert pressure on pricing. From a competitive standpoint, multiple third-generation EGFR-TKIs and next-generation targeted therapies from both domestic and international companies are continuously entering the market. In addition, the development of immunotherapy combination regimens is further intensifying competition. Therefore, the future market performance of furmonertinib mesylate will depend on its penetration in first-line treatment, expansion of indications (such as adjuvant therapy or additional mutation subtypes), and the accumulation of real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and pricing.
This report studies the global Furmonertinib Mesylate production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Furmonertinib Mesylate and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Furmonertinib Mesylate that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Furmonertinib Mesylate total production and demand, 2021-2032, (Units)
Global Furmonertinib Mesylate total production value, 2021-2032, (USD Million)
Global Furmonertinib Mesylate production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (Units), (based on production site)
Global Furmonertinib Mesylate consumption by region & country, CAGR, 2021-2032 & (Units)
U.S. VS China: Furmonertinib Mesylate domestic production, consumption, key domestic manufacturers and share
Global Furmonertinib Mesylate production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (Units)
Global Furmonertinib Mesylate production by Type, production, value, CAGR, 2021-2032, (USD Million) & (Units)
Global Furmonertinib Mesylate production by Application, production, value, CAGR, 2021-2032, (USD Million) & (Units)
This report profiles key players in the global Furmonertinib Mesylate market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Allist Pharmaceuticals, Jiangsu Allist Biopharmaceutical, TargetMol, MedChemExpress, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Furmonertinib Mesylate market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Furmonertinib Mesylate Market, By Region:
1. How big is the global Furmonertinib Mesylate market?
2. What is the demand of the global Furmonertinib Mesylate market?
3. What is the year over year growth of the global Furmonertinib Mesylate market?
4. What is the production and production value of the global Furmonertinib Mesylate market?
5. Who are the key producers in the global Furmonertinib Mesylate market?
6. What are the growth factors driving the market demand?
In 2025, global Furmonertinib Mesylate Tablets production reached approximately 380,000 units.Furmonertinib Mesylate is an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily used for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations or the T790M resistance mutation. It works by selectively and irreversibly inhibiting the kinase activity of mutant EGFR, thereby blocking tumor cell proliferation and survival signaling pathways and suppressing tumor growth. Furmonertinib mesylate is characterized by high selectivity for mutant EGFR, good central nervous system penetration, and a relatively manageable safety profile, making it clinically valuable in the treatment of advanced non-small cell lung cancer.
Furmonertinib Mesylate, as a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), operates in a rapidly developing and highly competitive segment of the non-small cell lung cancer (NSCLC) targeted therapy market, particularly demonstrating strong competitiveness in patients with EGFR mutations and T790M resistance mutations. With the large population of lung cancer patients and the continuous improvement in the penetration of genetic testing, the demand for precision medicine is steadily increasing, providing a solid market foundation for this class of drugs.
From a competitive landscape perspective, imported originator drugs represented by Osimertinib have long dominated the market. However, furmonertinib mesylate, leveraging its domestic R&D advantages, price competitiveness, and potential efficacy in patients with central nervous system metastases, is gradually gaining market share in China.
On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although healthcare cost-control measures and volume-based procurement policies continue to exert pressure on pricing. From a competitive standpoint, multiple third-generation EGFR-TKIs and next-generation targeted therapies from both domestic and international companies are continuously entering the market. In addition, the development of immunotherapy combination regimens is further intensifying competition. Therefore, the future market performance of furmonertinib mesylate will depend on its penetration in first-line treatment, expansion of indications (such as adjuvant therapy or additional mutation subtypes), and the accumulation of real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and pricing.
This report studies the global Furmonertinib Mesylate production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Furmonertinib Mesylate and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Furmonertinib Mesylate that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Furmonertinib Mesylate total production and demand, 2021-2032, (Units)
Global Furmonertinib Mesylate total production value, 2021-2032, (USD Million)
Global Furmonertinib Mesylate production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (Units), (based on production site)
Global Furmonertinib Mesylate consumption by region & country, CAGR, 2021-2032 & (Units)
U.S. VS China: Furmonertinib Mesylate domestic production, consumption, key domestic manufacturers and share
Global Furmonertinib Mesylate production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (Units)
Global Furmonertinib Mesylate production by Type, production, value, CAGR, 2021-2032, (USD Million) & (Units)
Global Furmonertinib Mesylate production by Application, production, value, CAGR, 2021-2032, (USD Million) & (Units)
This report profiles key players in the global Furmonertinib Mesylate market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Allist Pharmaceuticals, Jiangsu Allist Biopharmaceutical, TargetMol, MedChemExpress, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Furmonertinib Mesylate market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Furmonertinib Mesylate Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- 40 mg
- 80 mg
- Hospital
- Retail
- Online
- Non-small Cell Lung Cancer (NSCLC) Treatment
- Patients With Central Nervous System Metastases
- First-line and Later-line Targeted Therapy
- Others
- Allist Pharmaceuticals
- Jiangsu Allist Biopharmaceutical
- TargetMol
- MedChemExpress
1. How big is the global Furmonertinib Mesylate market?
2. What is the demand of the global Furmonertinib Mesylate market?
3. What is the year over year growth of the global Furmonertinib Mesylate market?
4. What is the production and production value of the global Furmonertinib Mesylate market?
5. Who are the key producers in the global Furmonertinib Mesylate market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Furmonertinib Mesylate Introduction
1.2 World Furmonertinib Mesylate Supply & Forecast
1.2.1 World Furmonertinib Mesylate Production Value (2021 & 2025 & 2032)
1.2.2 World Furmonertinib Mesylate Production (2021-2032)
1.2.3 World Furmonertinib Mesylate Pricing Trends (2021-2032)
1.3 World Furmonertinib Mesylate Production by Region (Based on Production Site)
1.3.1 World Furmonertinib Mesylate Production Value by Region (2021-2032)
1.3.2 World Furmonertinib Mesylate Production by Region (2021-2032)
1.3.3 World Furmonertinib Mesylate Average Price by Region (2021-2032)
1.3.4 North America Furmonertinib Mesylate Production (2021-2032)
1.3.5 Europe Furmonertinib Mesylate Production (2021-2032)
1.3.6 China Furmonertinib Mesylate Production (2021-2032)
1.3.7 Japan Furmonertinib Mesylate Production (2021-2032)
1.3.8 India Furmonertinib Mesylate Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Furmonertinib Mesylate Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Furmonertinib Mesylate Major Market Trends
2 DEMAND SUMMARY
2.1 World Furmonertinib Mesylate Demand (2021-2032)
2.2 World Furmonertinib Mesylate Consumption by Region
2.2.1 World Furmonertinib Mesylate Consumption by Region (2021-2026)
2.2.2 World Furmonertinib Mesylate Consumption Forecast by Region (2027-2032)
2.3 United States Furmonertinib Mesylate Consumption (2021-2032)
2.4 China Furmonertinib Mesylate Consumption (2021-2032)
2.5 Europe Furmonertinib Mesylate Consumption (2021-2032)
2.6 Japan Furmonertinib Mesylate Consumption (2021-2032)
2.7 South Korea Furmonertinib Mesylate Consumption (2021-2032)
2.8 ASEAN Furmonertinib Mesylate Consumption (2021-2032)
2.9 India Furmonertinib Mesylate Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Furmonertinib Mesylate Production Value by Manufacturer (2021-2026)
3.2 World Furmonertinib Mesylate Production by Manufacturer (2021-2026)
3.3 World Furmonertinib Mesylate Average Price by Manufacturer (2021-2026)
3.4 Furmonertinib Mesylate Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Furmonertinib Mesylate Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Furmonertinib Mesylate in 2025
3.5.3 Global Concentration Ratios (CR8) for Furmonertinib Mesylate in 2025
3.6 Furmonertinib Mesylate Market: Overall Company Footprint Analysis
3.6.1 Furmonertinib Mesylate Market: Region Footprint
3.6.2 Furmonertinib Mesylate Market: Company Product Type Footprint
3.6.3 Furmonertinib Mesylate Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Furmonertinib Mesylate Production Value Comparison
4.1.1 United States VS China: Furmonertinib Mesylate Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Furmonertinib Mesylate Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Furmonertinib Mesylate Production Comparison
4.2.1 United States VS China: Furmonertinib Mesylate Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Furmonertinib Mesylate Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Furmonertinib Mesylate Consumption Comparison
4.3.1 United States VS China: Furmonertinib Mesylate Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Furmonertinib Mesylate Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Furmonertinib Mesylate Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Furmonertinib Mesylate Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Furmonertinib Mesylate Production Value (2021-2026)
4.4.3 United States Based Manufacturers Furmonertinib Mesylate Production (2021-2026)
4.5 China Based Furmonertinib Mesylate Manufacturers and Market Share
4.5.1 China Based Furmonertinib Mesylate Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Furmonertinib Mesylate Production Value (2021-2026)
4.5.3 China Based Manufacturers Furmonertinib Mesylate Production (2021-2026)
4.6 Rest of World Based Furmonertinib Mesylate Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Furmonertinib Mesylate Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Furmonertinib Mesylate Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Furmonertinib Mesylate Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Furmonertinib Mesylate Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 40 mg
5.2.2 80 mg
5.3 Market Segment by Type
5.3.1 World Furmonertinib Mesylate Production by Type (2021-2032)
5.3.2 World Furmonertinib Mesylate Production Value by Type (2021-2032)
5.3.3 World Furmonertinib Mesylate Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY SALES CHANNELS
6.1 World Furmonertinib Mesylate Market Size Overview by Sales Channels: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Sales Channels
6.2.1 Hospital
6.2.2 Retail
6.2.3 Online
6.3 Market Segment by Sales Channels
6.3.1 World Furmonertinib Mesylate Production by Sales Channels (2021-2032)
6.3.2 World Furmonertinib Mesylate Production Value by Sales Channels (2021-2032)
6.3.3 World Furmonertinib Mesylate Average Price by Sales Channels (2021-2032)
7 MARKET ANALYSIS BY APPLICATION
7.1 World Furmonertinib Mesylate Market Size Overview by Application: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Application
7.2.1 Non-small Cell Lung Cancer (NSCLC) Treatment
7.2.2 Patients With Central Nervous System Metastases
7.2.3 First-line and Later-line Targeted Therapy
7.2.4 Others
7.3 Market Segment by Application
7.3.1 World Furmonertinib Mesylate Production by Application (2021-2032)
7.3.2 World Furmonertinib Mesylate Production Value by Application (2021-2032)
7.3.3 World Furmonertinib Mesylate Average Price by Application (2021-2032)
8 COMPANY PROFILES
8.1 Allist Pharmaceuticals
8.1.1 Allist Pharmaceuticals Details
8.1.2 Allist Pharmaceuticals Major Business
8.1.3 Allist Pharmaceuticals Furmonertinib Mesylate Product and Services
8.1.4 Allist Pharmaceuticals Furmonertinib Mesylate Production, Price, Value, Gross Margin and Market Share (2021-2026)
8.1.5 Allist Pharmaceuticals Recent Developments/Updates
8.1.6 Allist Pharmaceuticals Competitive Strengths & Weaknesses
8.2 Jiangsu Allist Biopharmaceutical
8.2.1 Jiangsu Allist Biopharmaceutical Details
8.2.2 Jiangsu Allist Biopharmaceutical Major Business
8.2.3 Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Product and Services
8.2.4 Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Production, Price, Value, Gross Margin and Market Share (2021-2026)
8.2.5 Jiangsu Allist Biopharmaceutical Recent Developments/Updates
8.2.6 Jiangsu Allist Biopharmaceutical Competitive Strengths & Weaknesses
8.3 TargetMol
8.3.1 TargetMol Details
8.3.2 TargetMol Major Business
8.3.3 TargetMol Furmonertinib Mesylate Product and Services
8.3.4 TargetMol Furmonertinib Mesylate Production, Price, Value, Gross Margin and Market Share (2021-2026)
8.3.5 TargetMol Recent Developments/Updates
8.3.6 TargetMol Competitive Strengths & Weaknesses
8.4 MedChemExpress
8.4.1 MedChemExpress Details
8.4.2 MedChemExpress Major Business
8.4.3 MedChemExpress Furmonertinib Mesylate Product and Services
8.4.4 MedChemExpress Furmonertinib Mesylate Production, Price, Value, Gross Margin and Market Share (2021-2026)
8.4.5 MedChemExpress Recent Developments/Updates
8.4.6 MedChemExpress Competitive Strengths & Weaknesses
9 INDUSTRY CHAIN ANALYSIS
9.1 Furmonertinib Mesylate Industry Chain
9.2 Furmonertinib Mesylate Upstream Analysis
9.2.1 Furmonertinib Mesylate Core Raw Materials
9.2.2 Main Manufacturers of Furmonertinib Mesylate Core Raw Materials
9.3 Midstream Analysis
9.4 Downstream Analysis
9.5 Furmonertinib Mesylate Production Mode
9.6 Furmonertinib Mesylate Procurement Model
9.7 Furmonertinib Mesylate Industry Sales Model and Sales Channels
9.7.1 Furmonertinib Mesylate Sales Model
9.7.2 Furmonertinib Mesylate Typical Distributors
10 RESEARCH FINDINGS AND CONCLUSION
11 APPENDIX
11.1 Methodology
11.2 Research Process and Data Source
11.3 Disclaimer
1.1 Furmonertinib Mesylate Introduction
1.2 World Furmonertinib Mesylate Supply & Forecast
1.2.1 World Furmonertinib Mesylate Production Value (2021 & 2025 & 2032)
1.2.2 World Furmonertinib Mesylate Production (2021-2032)
1.2.3 World Furmonertinib Mesylate Pricing Trends (2021-2032)
1.3 World Furmonertinib Mesylate Production by Region (Based on Production Site)
1.3.1 World Furmonertinib Mesylate Production Value by Region (2021-2032)
1.3.2 World Furmonertinib Mesylate Production by Region (2021-2032)
1.3.3 World Furmonertinib Mesylate Average Price by Region (2021-2032)
1.3.4 North America Furmonertinib Mesylate Production (2021-2032)
1.3.5 Europe Furmonertinib Mesylate Production (2021-2032)
1.3.6 China Furmonertinib Mesylate Production (2021-2032)
1.3.7 Japan Furmonertinib Mesylate Production (2021-2032)
1.3.8 India Furmonertinib Mesylate Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Furmonertinib Mesylate Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Furmonertinib Mesylate Major Market Trends
2 DEMAND SUMMARY
2.1 World Furmonertinib Mesylate Demand (2021-2032)
2.2 World Furmonertinib Mesylate Consumption by Region
2.2.1 World Furmonertinib Mesylate Consumption by Region (2021-2026)
2.2.2 World Furmonertinib Mesylate Consumption Forecast by Region (2027-2032)
2.3 United States Furmonertinib Mesylate Consumption (2021-2032)
2.4 China Furmonertinib Mesylate Consumption (2021-2032)
2.5 Europe Furmonertinib Mesylate Consumption (2021-2032)
2.6 Japan Furmonertinib Mesylate Consumption (2021-2032)
2.7 South Korea Furmonertinib Mesylate Consumption (2021-2032)
2.8 ASEAN Furmonertinib Mesylate Consumption (2021-2032)
2.9 India Furmonertinib Mesylate Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Furmonertinib Mesylate Production Value by Manufacturer (2021-2026)
3.2 World Furmonertinib Mesylate Production by Manufacturer (2021-2026)
3.3 World Furmonertinib Mesylate Average Price by Manufacturer (2021-2026)
3.4 Furmonertinib Mesylate Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Furmonertinib Mesylate Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Furmonertinib Mesylate in 2025
3.5.3 Global Concentration Ratios (CR8) for Furmonertinib Mesylate in 2025
3.6 Furmonertinib Mesylate Market: Overall Company Footprint Analysis
3.6.1 Furmonertinib Mesylate Market: Region Footprint
3.6.2 Furmonertinib Mesylate Market: Company Product Type Footprint
3.6.3 Furmonertinib Mesylate Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Furmonertinib Mesylate Production Value Comparison
4.1.1 United States VS China: Furmonertinib Mesylate Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Furmonertinib Mesylate Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Furmonertinib Mesylate Production Comparison
4.2.1 United States VS China: Furmonertinib Mesylate Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Furmonertinib Mesylate Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Furmonertinib Mesylate Consumption Comparison
4.3.1 United States VS China: Furmonertinib Mesylate Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Furmonertinib Mesylate Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Furmonertinib Mesylate Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Furmonertinib Mesylate Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Furmonertinib Mesylate Production Value (2021-2026)
4.4.3 United States Based Manufacturers Furmonertinib Mesylate Production (2021-2026)
4.5 China Based Furmonertinib Mesylate Manufacturers and Market Share
4.5.1 China Based Furmonertinib Mesylate Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Furmonertinib Mesylate Production Value (2021-2026)
4.5.3 China Based Manufacturers Furmonertinib Mesylate Production (2021-2026)
4.6 Rest of World Based Furmonertinib Mesylate Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Furmonertinib Mesylate Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Furmonertinib Mesylate Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Furmonertinib Mesylate Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Furmonertinib Mesylate Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 40 mg
5.2.2 80 mg
5.3 Market Segment by Type
5.3.1 World Furmonertinib Mesylate Production by Type (2021-2032)
5.3.2 World Furmonertinib Mesylate Production Value by Type (2021-2032)
5.3.3 World Furmonertinib Mesylate Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY SALES CHANNELS
6.1 World Furmonertinib Mesylate Market Size Overview by Sales Channels: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Sales Channels
6.2.1 Hospital
6.2.2 Retail
6.2.3 Online
6.3 Market Segment by Sales Channels
6.3.1 World Furmonertinib Mesylate Production by Sales Channels (2021-2032)
6.3.2 World Furmonertinib Mesylate Production Value by Sales Channels (2021-2032)
6.3.3 World Furmonertinib Mesylate Average Price by Sales Channels (2021-2032)
7 MARKET ANALYSIS BY APPLICATION
7.1 World Furmonertinib Mesylate Market Size Overview by Application: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Application
7.2.1 Non-small Cell Lung Cancer (NSCLC) Treatment
7.2.2 Patients With Central Nervous System Metastases
7.2.3 First-line and Later-line Targeted Therapy
7.2.4 Others
7.3 Market Segment by Application
7.3.1 World Furmonertinib Mesylate Production by Application (2021-2032)
7.3.2 World Furmonertinib Mesylate Production Value by Application (2021-2032)
7.3.3 World Furmonertinib Mesylate Average Price by Application (2021-2032)
8 COMPANY PROFILES
8.1 Allist Pharmaceuticals
8.1.1 Allist Pharmaceuticals Details
8.1.2 Allist Pharmaceuticals Major Business
8.1.3 Allist Pharmaceuticals Furmonertinib Mesylate Product and Services
8.1.4 Allist Pharmaceuticals Furmonertinib Mesylate Production, Price, Value, Gross Margin and Market Share (2021-2026)
8.1.5 Allist Pharmaceuticals Recent Developments/Updates
8.1.6 Allist Pharmaceuticals Competitive Strengths & Weaknesses
8.2 Jiangsu Allist Biopharmaceutical
8.2.1 Jiangsu Allist Biopharmaceutical Details
8.2.2 Jiangsu Allist Biopharmaceutical Major Business
8.2.3 Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Product and Services
8.2.4 Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Production, Price, Value, Gross Margin and Market Share (2021-2026)
8.2.5 Jiangsu Allist Biopharmaceutical Recent Developments/Updates
8.2.6 Jiangsu Allist Biopharmaceutical Competitive Strengths & Weaknesses
8.3 TargetMol
8.3.1 TargetMol Details
8.3.2 TargetMol Major Business
8.3.3 TargetMol Furmonertinib Mesylate Product and Services
8.3.4 TargetMol Furmonertinib Mesylate Production, Price, Value, Gross Margin and Market Share (2021-2026)
8.3.5 TargetMol Recent Developments/Updates
8.3.6 TargetMol Competitive Strengths & Weaknesses
8.4 MedChemExpress
8.4.1 MedChemExpress Details
8.4.2 MedChemExpress Major Business
8.4.3 MedChemExpress Furmonertinib Mesylate Product and Services
8.4.4 MedChemExpress Furmonertinib Mesylate Production, Price, Value, Gross Margin and Market Share (2021-2026)
8.4.5 MedChemExpress Recent Developments/Updates
8.4.6 MedChemExpress Competitive Strengths & Weaknesses
9 INDUSTRY CHAIN ANALYSIS
9.1 Furmonertinib Mesylate Industry Chain
9.2 Furmonertinib Mesylate Upstream Analysis
9.2.1 Furmonertinib Mesylate Core Raw Materials
9.2.2 Main Manufacturers of Furmonertinib Mesylate Core Raw Materials
9.3 Midstream Analysis
9.4 Downstream Analysis
9.5 Furmonertinib Mesylate Production Mode
9.6 Furmonertinib Mesylate Procurement Model
9.7 Furmonertinib Mesylate Industry Sales Model and Sales Channels
9.7.1 Furmonertinib Mesylate Sales Model
9.7.2 Furmonertinib Mesylate Typical Distributors
10 RESEARCH FINDINGS AND CONCLUSION
11 APPENDIX
11.1 Methodology
11.2 Research Process and Data Source
11.3 Disclaimer
LIST OF TABLES
Table 1. World Furmonertinib Mesylate Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Furmonertinib Mesylate Production Value by Region (2021-2026) & (USD Million)
Table 3. World Furmonertinib Mesylate Production Value by Region (2027-2032) & (USD Million)
Table 4. World Furmonertinib Mesylate Production Value Market Share by Region (2021-2026)
Table 5. World Furmonertinib Mesylate Production Value Market Share by Region (2027-2032)
Table 6. World Furmonertinib Mesylate Production by Region (2021-2026) & (Units)
Table 7. World Furmonertinib Mesylate Production by Region (2027-2032) & (Units)
Table 8. World Furmonertinib Mesylate Production Market Share by Region (2021-2026)
Table 9. World Furmonertinib Mesylate Production Market Share by Region (2027-2032)
Table 10. World Furmonertinib Mesylate Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Furmonertinib Mesylate Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Furmonertinib Mesylate Major Market Trends
Table 13. World Furmonertinib Mesylate Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (Units)
Table 14. World Furmonertinib Mesylate Consumption by Region (2021-2026) & (Units)
Table 15. World Furmonertinib Mesylate Consumption Forecast by Region (2027-2032) & (Units)
Table 16. World Furmonertinib Mesylate Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Furmonertinib Mesylate Producers in 2025
Table 18. World Furmonertinib Mesylate Production by Manufacturer (2021-2026) & (Units)
Table 19. Production Market Share of Key Furmonertinib Mesylate Producers in 2025
Table 20. World Furmonertinib Mesylate Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Furmonertinib Mesylate Company Evaluation Quadrant
Table 22. World Furmonertinib Mesylate Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Furmonertinib Mesylate Production Site of Key Manufacturer
Table 24. Furmonertinib Mesylate Market: Company Product Type Footprint
Table 25. Furmonertinib Mesylate Market: Company Product Application Footprint
Table 26. Furmonertinib Mesylate Competitive Factors
Table 27. Furmonertinib Mesylate New Entrant and Capacity Expansion Plans
Table 28. Furmonertinib Mesylate Mergers & Acquisitions Activity
Table 29. United States VS China Furmonertinib Mesylate Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Furmonertinib Mesylate Production Comparison, (2021 & 2025 & 2032) & (Units)
Table 31. United States VS China Furmonertinib Mesylate Consumption Comparison, (2021 & 2025 & 2032) & (Units)
Table 32. United States Based Furmonertinib Mesylate Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Furmonertinib Mesylate Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Furmonertinib Mesylate Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Furmonertinib Mesylate Production (2021-2026) & (Units)
Table 36. United States Based Manufacturers Furmonertinib Mesylate Production Market Share (2021-2026)
Table 37. China Based Furmonertinib Mesylate Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Furmonertinib Mesylate Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Furmonertinib Mesylate Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Furmonertinib Mesylate Production, (2021-2026) & (Units)
Table 41. China Based Manufacturers Furmonertinib Mesylate Production Market Share (2021-2026)
Table 42. Rest of World Based Furmonertinib Mesylate Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Furmonertinib Mesylate Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Furmonertinib Mesylate Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Furmonertinib Mesylate Production, (2021-2026) & (Units)
Table 46. Rest of World Based Manufacturers Furmonertinib Mesylate Production Market Share (2021-2026)
Table 47. World Furmonertinib Mesylate Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Furmonertinib Mesylate Production by Type (2021-2026) & (Units)
Table 49. World Furmonertinib Mesylate Production by Type (2027-2032) & (Units)
Table 50. World Furmonertinib Mesylate Production Value by Type (2021-2026) & (USD Million)
Table 51. World Furmonertinib Mesylate Production Value by Type (2027-2032) & (USD Million)
Table 52. World Furmonertinib Mesylate Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World Furmonertinib Mesylate Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World Furmonertinib Mesylate Production Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 55. World Furmonertinib Mesylate Production by Sales Channels (2021-2026) & (Units)
Table 56. World Furmonertinib Mesylate Production by Sales Channels (2027-2032) & (Units)
Table 57. World Furmonertinib Mesylate Production Value by Sales Channels (2021-2026) & (USD Million)
Table 58. World Furmonertinib Mesylate Production Value by Sales Channels (2027-2032) & (USD Million)
Table 59. World Furmonertinib Mesylate Average Price by Sales Channels (2021-2026) & (US$/Unit)
Table 60. World Furmonertinib Mesylate Average Price by Sales Channels (2027-2032) & (US$/Unit)
Table 61. World Furmonertinib Mesylate Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 62. World Furmonertinib Mesylate Production by Application (2021-2026) & (Units)
Table 63. World Furmonertinib Mesylate Production by Application (2027-2032) & (Units)
Table 64. World Furmonertinib Mesylate Production Value by Application (2021-2026) & (USD Million)
Table 65. World Furmonertinib Mesylate Production Value by Application (2027-2032) & (USD Million)
Table 66. World Furmonertinib Mesylate Average Price by Application (2021-2026) & (US$/Unit)
Table 67. World Furmonertinib Mesylate Average Price by Application (2027-2032) & (US$/Unit)
Table 68. Allist Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 69. Allist Pharmaceuticals Major Business
Table 70. Allist Pharmaceuticals Furmonertinib Mesylate Product and Services
Table 71. Allist Pharmaceuticals Furmonertinib Mesylate Production (Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 72. Allist Pharmaceuticals Recent Developments/Updates
Table 73. Allist Pharmaceuticals Competitive Strengths & Weaknesses
Table 74. Jiangsu Allist Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 75. Jiangsu Allist Biopharmaceutical Major Business
Table 76. Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Product and Services
Table 77. Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Production (Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 78. Jiangsu Allist Biopharmaceutical Recent Developments/Updates
Table 79. Jiangsu Allist Biopharmaceutical Competitive Strengths & Weaknesses
Table 80. TargetMol Basic Information, Manufacturing Base and Competitors
Table 81. TargetMol Major Business
Table 82. TargetMol Furmonertinib Mesylate Product and Services
Table 83. TargetMol Furmonertinib Mesylate Production (Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 84. TargetMol Recent Developments/Updates
Table 85. TargetMol Competitive Strengths & Weaknesses
Table 86. MedChemExpress Basic Information, Manufacturing Base and Competitors
Table 87. MedChemExpress Major Business
Table 88. MedChemExpress Furmonertinib Mesylate Product and Services
Table 89. MedChemExpress Furmonertinib Mesylate Production (Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 90. MedChemExpress Recent Developments/Updates
Table 91. MedChemExpress Competitive Strengths & Weaknesses
Table 92. Global Key Players of Furmonertinib Mesylate Upstream (Raw Materials)
Table 93. Global Furmonertinib Mesylate Typical Customers
Table 94. Furmonertinib Mesylate Typical Distributors
Table 1. World Furmonertinib Mesylate Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Furmonertinib Mesylate Production Value by Region (2021-2026) & (USD Million)
Table 3. World Furmonertinib Mesylate Production Value by Region (2027-2032) & (USD Million)
Table 4. World Furmonertinib Mesylate Production Value Market Share by Region (2021-2026)
Table 5. World Furmonertinib Mesylate Production Value Market Share by Region (2027-2032)
Table 6. World Furmonertinib Mesylate Production by Region (2021-2026) & (Units)
Table 7. World Furmonertinib Mesylate Production by Region (2027-2032) & (Units)
Table 8. World Furmonertinib Mesylate Production Market Share by Region (2021-2026)
Table 9. World Furmonertinib Mesylate Production Market Share by Region (2027-2032)
Table 10. World Furmonertinib Mesylate Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Furmonertinib Mesylate Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Furmonertinib Mesylate Major Market Trends
Table 13. World Furmonertinib Mesylate Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (Units)
Table 14. World Furmonertinib Mesylate Consumption by Region (2021-2026) & (Units)
Table 15. World Furmonertinib Mesylate Consumption Forecast by Region (2027-2032) & (Units)
Table 16. World Furmonertinib Mesylate Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Furmonertinib Mesylate Producers in 2025
Table 18. World Furmonertinib Mesylate Production by Manufacturer (2021-2026) & (Units)
Table 19. Production Market Share of Key Furmonertinib Mesylate Producers in 2025
Table 20. World Furmonertinib Mesylate Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Furmonertinib Mesylate Company Evaluation Quadrant
Table 22. World Furmonertinib Mesylate Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Furmonertinib Mesylate Production Site of Key Manufacturer
Table 24. Furmonertinib Mesylate Market: Company Product Type Footprint
Table 25. Furmonertinib Mesylate Market: Company Product Application Footprint
Table 26. Furmonertinib Mesylate Competitive Factors
Table 27. Furmonertinib Mesylate New Entrant and Capacity Expansion Plans
Table 28. Furmonertinib Mesylate Mergers & Acquisitions Activity
Table 29. United States VS China Furmonertinib Mesylate Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Furmonertinib Mesylate Production Comparison, (2021 & 2025 & 2032) & (Units)
Table 31. United States VS China Furmonertinib Mesylate Consumption Comparison, (2021 & 2025 & 2032) & (Units)
Table 32. United States Based Furmonertinib Mesylate Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Furmonertinib Mesylate Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Furmonertinib Mesylate Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Furmonertinib Mesylate Production (2021-2026) & (Units)
Table 36. United States Based Manufacturers Furmonertinib Mesylate Production Market Share (2021-2026)
Table 37. China Based Furmonertinib Mesylate Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Furmonertinib Mesylate Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Furmonertinib Mesylate Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Furmonertinib Mesylate Production, (2021-2026) & (Units)
Table 41. China Based Manufacturers Furmonertinib Mesylate Production Market Share (2021-2026)
Table 42. Rest of World Based Furmonertinib Mesylate Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Furmonertinib Mesylate Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Furmonertinib Mesylate Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Furmonertinib Mesylate Production, (2021-2026) & (Units)
Table 46. Rest of World Based Manufacturers Furmonertinib Mesylate Production Market Share (2021-2026)
Table 47. World Furmonertinib Mesylate Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Furmonertinib Mesylate Production by Type (2021-2026) & (Units)
Table 49. World Furmonertinib Mesylate Production by Type (2027-2032) & (Units)
Table 50. World Furmonertinib Mesylate Production Value by Type (2021-2026) & (USD Million)
Table 51. World Furmonertinib Mesylate Production Value by Type (2027-2032) & (USD Million)
Table 52. World Furmonertinib Mesylate Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World Furmonertinib Mesylate Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World Furmonertinib Mesylate Production Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 55. World Furmonertinib Mesylate Production by Sales Channels (2021-2026) & (Units)
Table 56. World Furmonertinib Mesylate Production by Sales Channels (2027-2032) & (Units)
Table 57. World Furmonertinib Mesylate Production Value by Sales Channels (2021-2026) & (USD Million)
Table 58. World Furmonertinib Mesylate Production Value by Sales Channels (2027-2032) & (USD Million)
Table 59. World Furmonertinib Mesylate Average Price by Sales Channels (2021-2026) & (US$/Unit)
Table 60. World Furmonertinib Mesylate Average Price by Sales Channels (2027-2032) & (US$/Unit)
Table 61. World Furmonertinib Mesylate Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 62. World Furmonertinib Mesylate Production by Application (2021-2026) & (Units)
Table 63. World Furmonertinib Mesylate Production by Application (2027-2032) & (Units)
Table 64. World Furmonertinib Mesylate Production Value by Application (2021-2026) & (USD Million)
Table 65. World Furmonertinib Mesylate Production Value by Application (2027-2032) & (USD Million)
Table 66. World Furmonertinib Mesylate Average Price by Application (2021-2026) & (US$/Unit)
Table 67. World Furmonertinib Mesylate Average Price by Application (2027-2032) & (US$/Unit)
Table 68. Allist Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 69. Allist Pharmaceuticals Major Business
Table 70. Allist Pharmaceuticals Furmonertinib Mesylate Product and Services
Table 71. Allist Pharmaceuticals Furmonertinib Mesylate Production (Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 72. Allist Pharmaceuticals Recent Developments/Updates
Table 73. Allist Pharmaceuticals Competitive Strengths & Weaknesses
Table 74. Jiangsu Allist Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 75. Jiangsu Allist Biopharmaceutical Major Business
Table 76. Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Product and Services
Table 77. Jiangsu Allist Biopharmaceutical Furmonertinib Mesylate Production (Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 78. Jiangsu Allist Biopharmaceutical Recent Developments/Updates
Table 79. Jiangsu Allist Biopharmaceutical Competitive Strengths & Weaknesses
Table 80. TargetMol Basic Information, Manufacturing Base and Competitors
Table 81. TargetMol Major Business
Table 82. TargetMol Furmonertinib Mesylate Product and Services
Table 83. TargetMol Furmonertinib Mesylate Production (Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 84. TargetMol Recent Developments/Updates
Table 85. TargetMol Competitive Strengths & Weaknesses
Table 86. MedChemExpress Basic Information, Manufacturing Base and Competitors
Table 87. MedChemExpress Major Business
Table 88. MedChemExpress Furmonertinib Mesylate Product and Services
Table 89. MedChemExpress Furmonertinib Mesylate Production (Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 90. MedChemExpress Recent Developments/Updates
Table 91. MedChemExpress Competitive Strengths & Weaknesses
Table 92. Global Key Players of Furmonertinib Mesylate Upstream (Raw Materials)
Table 93. Global Furmonertinib Mesylate Typical Customers
Table 94. Furmonertinib Mesylate Typical Distributors
LIST OF FIGURES
Figure 1. Furmonertinib Mesylate Picture
Figure 2. World Furmonertinib Mesylate Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Furmonertinib Mesylate Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Furmonertinib Mesylate Production (2021-2032) & (Units)
Figure 5. World Furmonertinib Mesylate Average Price (2021-2032) & (US$/Unit)
Figure 6. World Furmonertinib Mesylate Production Value Market Share by Region (2021-2032)
Figure 7. World Furmonertinib Mesylate Production Market Share by Region (2021-2032)
Figure 8. North America Furmonertinib Mesylate Production (2021-2032) & (Units)
Figure 9. Europe Furmonertinib Mesylate Production (2021-2032) & (Units)
Figure 10. China Furmonertinib Mesylate Production (2021-2032) & (Units)
Figure 11. Japan Furmonertinib Mesylate Production (2021-2032) & (Units)
Figure 12. India Furmonertinib Mesylate Production (2021-2032) & (Units)
Figure 13. Furmonertinib Mesylate Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 16. World Furmonertinib Mesylate Consumption Market Share by Region (2021-2032)
Figure 17. United States Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 18. China Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 19. Europe Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 20. Japan Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 21. South Korea Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 22. ASEAN Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 23. India Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 24. Producer Shipments of Furmonertinib Mesylate by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Furmonertinib Mesylate Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Furmonertinib Mesylate Markets in 2025
Figure 27. United States VS China: Furmonertinib Mesylate Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Furmonertinib Mesylate Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Furmonertinib Mesylate Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers Furmonertinib Mesylate Production Market Share 2025
Figure 31. China Based Manufacturers Furmonertinib Mesylate Production Market Share 2025
Figure 32. Rest of World Based Manufacturers Furmonertinib Mesylate Production Market Share 2025
Figure 33. World Furmonertinib Mesylate Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World Furmonertinib Mesylate Production Value Market Share by Type in 2025
Figure 35. 40 mg
Figure 36. 80 mg
Figure 37. World Furmonertinib Mesylate Production Market Share by Type (2021-2032)
Figure 38. World Furmonertinib Mesylate Production Value Market Share by Type (2021-2032)
Figure 39. World Furmonertinib Mesylate Average Price by Type (2021-2032) & (US$/Unit)
Figure 40. World Furmonertinib Mesylate Production Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 41. World Furmonertinib Mesylate Production Value Market Share by Sales Channels in 2025
Figure 42. Hospital
Figure 43. Retail
Figure 44. Online
Figure 45. World Furmonertinib Mesylate Production Market Share by Sales Channels (2021-2032)
Figure 46. World Furmonertinib Mesylate Production Value Market Share by Sales Channels (2021-2032)
Figure 47. World Furmonertinib Mesylate Average Price by Sales Channels (2021-2032) & (US$/Unit)
Figure 48.Tablets
Figure 49. Powder
Figure 50. World Furmonertinib Mesylate Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 51. World Furmonertinib Mesylate Production Value Market Share by Application in 2025
Figure 52. Non-small Cell Lung Cancer (NSCLC) Treatment
Figure 53. Patients With Central Nervous System Metastases
Figure 54. First-line and Later-line Targeted Therapy
Figure 55. Others
Figure 56. World Furmonertinib Mesylate Production Market Share by Application (2021-2032)
Figure 57. World Furmonertinib Mesylate Production Value Market Share by Application (2021-2032)
Figure 58. World Furmonertinib Mesylate Average Price by Application (2021-2032) & (US$/Unit)
Figure 59. Furmonertinib Mesylate Industry Chain
Figure 60. Furmonertinib Mesylate Procurement Model
Figure 61. Furmonertinib Mesylate Sales Model
Figure 62. Furmonertinib Mesylate Sales Channels, Direct Sales, and Distribution
Figure 63. Methodology
Figure 64. Research Process and Data Source
Figure 1. Furmonertinib Mesylate Picture
Figure 2. World Furmonertinib Mesylate Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Furmonertinib Mesylate Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Furmonertinib Mesylate Production (2021-2032) & (Units)
Figure 5. World Furmonertinib Mesylate Average Price (2021-2032) & (US$/Unit)
Figure 6. World Furmonertinib Mesylate Production Value Market Share by Region (2021-2032)
Figure 7. World Furmonertinib Mesylate Production Market Share by Region (2021-2032)
Figure 8. North America Furmonertinib Mesylate Production (2021-2032) & (Units)
Figure 9. Europe Furmonertinib Mesylate Production (2021-2032) & (Units)
Figure 10. China Furmonertinib Mesylate Production (2021-2032) & (Units)
Figure 11. Japan Furmonertinib Mesylate Production (2021-2032) & (Units)
Figure 12. India Furmonertinib Mesylate Production (2021-2032) & (Units)
Figure 13. Furmonertinib Mesylate Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 16. World Furmonertinib Mesylate Consumption Market Share by Region (2021-2032)
Figure 17. United States Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 18. China Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 19. Europe Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 20. Japan Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 21. South Korea Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 22. ASEAN Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 23. India Furmonertinib Mesylate Consumption (2021-2032) & (Units)
Figure 24. Producer Shipments of Furmonertinib Mesylate by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Furmonertinib Mesylate Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Furmonertinib Mesylate Markets in 2025
Figure 27. United States VS China: Furmonertinib Mesylate Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Furmonertinib Mesylate Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Furmonertinib Mesylate Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers Furmonertinib Mesylate Production Market Share 2025
Figure 31. China Based Manufacturers Furmonertinib Mesylate Production Market Share 2025
Figure 32. Rest of World Based Manufacturers Furmonertinib Mesylate Production Market Share 2025
Figure 33. World Furmonertinib Mesylate Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World Furmonertinib Mesylate Production Value Market Share by Type in 2025
Figure 35. 40 mg
Figure 36. 80 mg
Figure 37. World Furmonertinib Mesylate Production Market Share by Type (2021-2032)
Figure 38. World Furmonertinib Mesylate Production Value Market Share by Type (2021-2032)
Figure 39. World Furmonertinib Mesylate Average Price by Type (2021-2032) & (US$/Unit)
Figure 40. World Furmonertinib Mesylate Production Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 41. World Furmonertinib Mesylate Production Value Market Share by Sales Channels in 2025
Figure 42. Hospital
Figure 43. Retail
Figure 44. Online
Figure 45. World Furmonertinib Mesylate Production Market Share by Sales Channels (2021-2032)
Figure 46. World Furmonertinib Mesylate Production Value Market Share by Sales Channels (2021-2032)
Figure 47. World Furmonertinib Mesylate Average Price by Sales Channels (2021-2032) & (US$/Unit)
Figure 48.Tablets
Figure 49. Powder
Figure 50. World Furmonertinib Mesylate Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 51. World Furmonertinib Mesylate Production Value Market Share by Application in 2025
Figure 52. Non-small Cell Lung Cancer (NSCLC) Treatment
Figure 53. Patients With Central Nervous System Metastases
Figure 54. First-line and Later-line Targeted Therapy
Figure 55. Others
Figure 56. World Furmonertinib Mesylate Production Market Share by Application (2021-2032)
Figure 57. World Furmonertinib Mesylate Production Value Market Share by Application (2021-2032)
Figure 58. World Furmonertinib Mesylate Average Price by Application (2021-2032) & (US$/Unit)
Figure 59. Furmonertinib Mesylate Industry Chain
Figure 60. Furmonertinib Mesylate Procurement Model
Figure 61. Furmonertinib Mesylate Sales Model
Figure 62. Furmonertinib Mesylate Sales Channels, Direct Sales, and Distribution
Figure 63. Methodology
Figure 64. Research Process and Data Source
